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ABSTRACT
MEASUREMENT OF THE EFFECTIVENESS OF ENHANCED EXTERNAL
COUNTERPULSATION ON HEART RATE VARIABILITY FOR PATIENTS
WITH MYOCARDIAL ISCHEMIA
by
Kripa Jayaraman
This thesis is a study to measure the changes in heart rate variability due to the activity of
the autonomic nervous system caused by the Enhanced External Counterpulsation
treatment. The treatment is a non surgical, mechanical procedure that can reduce the
symptoms of angina or Congestive Heart Failure, presumably by stimulating the opening,
or formation of, small branches of blood vessels (collaterals) to create a natural bypass
around narrowed or blocked arteries. It has been proved that rhythms can be markers of
normal functional states. Even in the absence of external perturbations, the normal
heartbeat is not characterized by clockwise regularity. This fluctuation around the mean
heart rate is called heart rate variability. The study was conducted on patients who had
myocardial ischemia and had been prescribed enhanced external counterpulsation
treatment by the physician. One of the patients was a non-ischemic heart failure patient
who had heart failure secondary to dilated cardiomyopathy. Myocardial ischemia is a
condition in which oxygen deprivation to the heart muscle is accompanied by inadequate
removal of metabolites because of reduced blood flow or perfusion.
The study was conducted on three subject groups — 7 patients, 5 controls and 3
normals. Normals had no history of myocardial ischemia, but underwent the EECP
treatment while controls were healthy and did not undergo the treatment. The subjects
followed paced breathing at the rate of 12 breaths per minute. The data were collected
during five minute paced breathing before and after the EECP treatment except for the

controls. The waveforms of ECG, respiration and blood pressure were collected as data
from the subjects. Frequency domain-power spectral analysis was performed on the data
obtained using the LabVIEW 5.0 software. The time domain-SDNN analysis was also
performed using MATLAB.
The results of this study fail to indicate conclusively that the EECP treatment
affects the heart rate variability of the patient in a significant way. This was evidenced by
conducting Power Spectral Analysis and Standard Deviation of Normal to Normal
intervals on the analyzed data for the research.
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CHAPTER 1
OVERVIEW

This research was focused on measuring the changes in heart rate variability due to the
activity of the autonomic nervous system caused by the Enhanced External
Counterpulsation treatment. The patients involved in the research had a history of
myocardial ischemia. One of the patients was a non-ischemic heart failure patient, i.e.,
heart failure secondary to dilated cardiomyopathy. To treat the patients, the physicians
prescribed the Enhanced External Counterpulsation treatment. To better understand the
changes occurring in the body during the duration of the counterpulsation treatment, it is
important to understand the functioning of the heart, the changes it undergoes because of
the diseased state and the changes observed after this treatment. This change was
quantified by measuring the heart rate variability of the subjects. At the beginning of the
research, it was hypothesized that the heart variability of the patients would increase over
the seven weeks of the treatment. Since heart rate variability is known to be reduced in
patients who survived myocardial ischemia, it was hypothesized that the treatment would
lead to an increase in the HRV.
In order to analyze and compare the data, there were three groups of subjectspatients, normals and controls. Patients were the subjects who had a history of
myocardial ischemia and underwent the EECP treatment, normals were healthy but
underwent the EECP treatment, while the controls were healthy but did not undergo the
treatment. Tools like power spectral analysis, standard deviation of R-to-R interval
(SDNN) and T tests were used to analyze the data.
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CHAPTER 2
PHYSIOLOGICAL BACKGROUND

This chapter will serve as a brief overview of the biological basis of the
electrocardiogram, respiration and blood pressure signals used in this study. The
overview also covers the physiological background of the heart, its functions and its
diseased state. Also, the chapter details the physiological systems evaluated.

2.1 Statement of Objective
The objective of this research was to measure the heart rate variability of patients after
the enhanced external counterpulsation treatment. These patients had a history of
myocardial ischemic. One of the patients had heart failure secondary to ischemic
cardiomyopathy. To better understand the changes occurring in the body during the
duration of the counterpulsation treatment, it is important to understand the functioning
of the heart, the changes it undergoes because of the diseased state and the changes
observed after this treatment. To categorize these changes, various analytical and
statistical tools like power spectral analysis, SDNN and t tests have been used.

2.2 Functioning of the Heart
Dark blood, low in oxygen, flows through veins to the heart and enters the right atrium. It
passes through the tricuspid valve into the right ventricle. The right ventricle pumps the
blood under low pressure through the pulmonary valve into the pulmonary artery. The
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pulmonary artery branches into the left and right pulmonary arteries, which lead to the
lungs [1]. The lungs provide fresh oxygen to the circulating blood.

Figure 2.1 Structure of the heart.

Figure 2.1 shows the structure of the heart. Blood returns to the heart from the
lungs by the left and right pulmonary veins. It enters the left atrium. From there it flows
through the mitral valve and enters the left ventricle. This strong chamber pumps the red
oxygen-rich blood out through the aortic valve into the aorta. The aorta takes blood to the
body's general circulation, as shown in Figure 2.2. The heart, just like all other muscles in
the body, needs its own supply of oxygen in order to function properly. Although its
chambers contain blood, the heart receives no nourishment from the blood inside the
chambers. The heart gets its blood supply from the coronary arteries. The two major
coronary arteries branch off the aorta, and then divide into many smaller arteries
that lie in the heart muscle and feed the heart [2].
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The cardiac cycle (heart beat) consists of cardiac muscle contraction (systole) and
cardiac muscle relaxation (diastole). Blood pressure represents the force (pressure)
exerted by blood against the arterial walls during a cardiac cycle. Systolic blood pressure,
the higher of the two pressure measurements, occurs during ventricular contraction
(systole) as the heart pumps blood into the aorta [1]. After systole, the ventricles relax
(diastole), arterial pressure declines and the heart refills with blood. The lowest pressure
reached during ventricular relaxation represents the diastolic blood pressure.
Heart rate is normally determined by the rate of depolarization of the cardiac
pacemaker. The pacemaker is found in the sinuatrial node, the atrioventricular node and
the Purkinje tissue. However, because the rate of depolarization is faster than that of the
other pacemaker tissue and the depolarizing impulse spreads via the heart's conducting
mechanism to other pacemakers before they spontaneously depolarize, it is the sinuatrial
node which determines the rate [3].
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2.3 Myocardial Ischemia
Insufficient blood supply to the myocardium can result in myocardial ischemia, injury or
infarction, or all three. Myocardial ischemia generally appears first and is more extensive
in the sub-endocardial region since these deeper myocardial layers are farthest from the
blood supply, with greater need for oxygen. Myocardial ischernia is a condition in which
oxygen deprivation to the heart muscle is accompanied by inadequate removal of
metabolites because of reduced blood flow or perfusion. During ischemia, an imbalance
occurs between myocardial oxygen supply and demand.

2.4 Causes of Myocardial Ischemia
Myocardial ischemia can occur as a result of increased myocardial oxygen demand,
reduced myocardial oxygen supply, or both. In the presence of coronary obstruction, an
increase of myocardial oxygen requirements caused by exercise, tachycardia, or emotion
leads to a transitory imbalance. This condition is frequently termed "demand" ischemia
and is responsible for most episodes of chronic stable angina. In other situations, the
imbalance is caused by acute reduction of oxygen supply secondary to increased coronary
vascular tone or by marked reduction or cessation of coronary flow as a result of platelet
aggregates or thrombi [6]. This condition, termed "supply" ischemia, is responsible for
myocardial infarction and most episodes of unstable angina. In many circumstances,
ischemia results from both an increase in oxygen demand and a reduction in supply.
The heart is an aerobic organ and therefore relies almost exclusively on the
oxidation of substrates for generation of energy. It can develop only a small oxygen debt
and still have enough energy to function normally. Thus, in a steady state, determination
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of the rate of myocardial oxygen consumption provides an accurate measure of its total
metabolism. Myocardial oxygen consumption is the product of systolic blood pressure
and heart rate [7]. The small fraction of MV02 in the non-contracting heart is required
for those physiologic processes not directly associated with contraction. Increases in the
frequency of depolarization of the non-contracting heart are accompanied by only small
increases in myocardial oxygen consumption.
Medically, the way to identify Myocardial Ischemia is (1) Anginal discomfort, (2)
ST-segment deviation on the ECG (Fig 2.2) (3) Reduced uptake of thallium 201 or
technetium 99 in myocardial perfusion images, or (4) Regional or global impairment of
ventricular function [8]. Usually, a S-T depression is associated with myocardial
ischemia when the S-T segment is 1 mm or more below the isoelectric line at the J point
[6]. Notice in the picture that it is the S-T segment, not just the T wave that is important.

Figure 2.3 S-T depression in the ECG of the Heart.

As the heart undergoes depolarization and repolarization, the electrical currents
that are generated spread not only within the heart, but also throughout the body. This
electrical activity generated by the heart is generally measured by an array of electrodes
placed on the body surface and the resulting tracing is called an electrocardiogram (ECG,
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or EKG). The P-wave represents the wave of depolarization that spreads from the SA
node throughout the atria and is usually 0.08 to 0.1 seconds (80-100 ms) in duration. The
period of time from the onset of the P-wave to the beginning of the QRS is termed the PR
interval and normally ranges from 0.12 to 0.20 seconds [9].

This interval represents the time between the onset of atrial depolarization and the
onset of ventricular depolarization. The QRS complex represents ventricular
depolarization. The duration of the QRS complex is normally 0.06 to 0.1 seconds
indicating that ventricular depolarization normally occurs very rapidly. The isoelectric
period (ST segment) following the QRS is the time at which the entire ventricle is
depolarized and roughly corresponds to the plateau phase of the ventricular action
potential. The ST segment is important in the diagnosis of ventricular ischemia or
hypoxia because under those conditions, the ST segment can become either depressed or
elevated. The 1-wave represents ventricular repolarization and is longer in duration than
depolarization (i.e., conduction of the repolarization wave is slower than the wave of
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depolarization) [8]. RR interval is used as a measure of heart period as the R peak is
more identifiable on the ECG tracing and the PR interval is constant in the absence of
conduction disorders.

CHAPTER 3
ENHANCED EXTERNAL COUNTERPULSATION

This chapter will serve as an overview of the counterpulsation technique, as well as an
overview of the physiological background and procedure. This chapter details both the
physiological systems evaluated and the method by which the data was acquired for this
research.

3.1 Introduction
Enhanced External Counterpulsation (EECP) is a non-invasive procedure that has shown
to reduce the symptoms of angina pectoris by increasing the coronary blood flow in the
ischemic areas of the heart [10]. It is an outpatient procedure that relieves myocardial
ischemia by improving perfusion in areas of the heart deprived of adequate blood supply.
Counterpulsation is a strategy for increasing the blood flow back to the heart during a
specific part of the heartbeat i.e. diastole when the heart needs oxygen rich blood [10].
This strategy not only increases the amount of oxygen available to the heart, but it also
decreases the heart's workload, improves circulation and strengthens the
cardiopulmonary system. The patients receive 35 sessions, with each session consisting
of a one-hour treatment, which is aimed at provoking long lasting beneficial changes in
the circulatory system [11]. The goal of the procedure is to increase oxygen rich blood
flow to the heart and to reduce the heart's workload by stimulating the opening, or
formation of, small branches of blood vessels to create natural bypass around narrowed or
blocked arteries [10]. This theory will be explained in detail in Section 3.4.
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3.2 History of Enhanced External Counterpulsation
Since the advent of bypass surgery in 1966 and coronary angioplasty in 1977, there has
been an explosion in the arena of coronary revascularization for atherosclerotic disease
[12]. Even with the successes of reoperation and catheter-based revascularization
techniques, the population of patients with intractable angina and no conventional
revascularization options is increasing.
Enhanced external counterpulsation was used as a treatment for angina in China
for two decades [12]. This noninvasive technique provides augmentation of diastolic
blood flow and coronary blood flow similar to the intra-aortic balloon pump, utilizing the
serial inflation of three sets of cuffs which wrap around the calves, thighs and buttocks.
Inflation and deflation is timed to the patient's ECG. The overall hemodynamic effect is
to provide diastolic augmentation and thus increase coronary perfusion pressure; to
unload systolic cardiac workload and therefore decrease myocardial oxygen demand; and
to increase venous return and subsequently, cardiac output. This exciting new therapy is
being advised more and more for patients who have chronic angina, acute ischemic
syndromes and cardiac dysfunction [12].
In 1953, Kantrowitz and Kantrowitz initially described the concept of diastolic
augmentation as a technique to improve coronary flow, which had been known to be
primarily diastolic [13]. Early work by Birtwell and others showed that the ECG QRS
complex could be utilized to time an external pumping device that provided a
synchronous pulse wave thereby increasing the development of coronary collaterals in
experimental models. Also, it was described how these types of assist devices could not
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only produce increased coronary flow, but also reduce left ventricular work and oxygen
demand.
The term counterpulsation was first coined to describe the two-fold effect of the
rapid displacement of the blood through the vessels and reduced resistance to the volume
of the blood in the lower arterial circuit. The principle thought to be in effect is that, via
persistent augmentation of diastolic flow, stimulation of collaterals to ischemic territories
occurs with improvement in symptoms and clinical measures of ischemic. Initial
experience with a crude external counterpulsation device used in stable angina saw relief
of angina symptoms with angiographic evidence of increased vascularity [12]. In the
early 1980's, a Chinese group lead by Z.S. Zheng began reporting a large experience
using a sequential three-cuff external counterpulsation system, which provided a pressure
wave by sequentially inflating from calf to thigh to buttock. Their clinical experience led
to the development and refinement of the EECP technique and device [12].

3.3 Physiological Background
The basic concept is based on the response of the left ventricle to reduce arterial pressure
during the systolic period so that the heart can be rested. The heart can be rested if the
oxygen demand can be reduced. 0xygen can be reduced if the left ventricular pressure
can be reduced. The net perfusion pressure must be maintained to meet the metabolic
needs of the body. Under the circumstance of decreased systolic pressure, the diastolic
pressure must be increased to maintain that effective perfusion. To achieve this, a system
is required that can be synchronized and phased with the cardiac activity.
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Repeated and pulsed increases in diastolic pressure during the therapy with EECP
enhance or stimulate the opening of collateral channels in the coronary vascular system,
increasing perfusion of ischemic areas. The earlier external counterpulsation systems
employed non-sequenced pulsation, i.e., compression of the vessels was performed
simultaneously along the full length of the compression element. Results could have been
improved if the blood was expressed from the extremities in a sequential manner. After
developing and testing these techniques, it was determined that greater cardiac output and
increase of the ratio of diastolic to systolic pressures were achieved with sequenced
systems than with the non-sequenced systems [14]. The EECP treatment employs a threecuff compression configuration and sophisticated computerized control of the inflation
and deflation sequence.
The pulsation is coordinated with the heartbeat. The systolic phase of the heart
muscle is the contraction of the ventricles that drives the blood into the aorta and
pulmonary artery. The diastolic phase is the resting time between the contractions, when
the ventricle fills with blood. The external counterpulsation equipment includes large
blood pressure cuffs wrapped around the legs that operate in synchrony with the person's
electrocardiogram [15]. The cuffs inflate during the diastolic phase of the heartbeat,
wrapped around the legs and pushing the venous blood sequentially from the calves,
thighs and buttocks towards the heart. This also increases oxygenated blood flow
upwards, supplying greater blood flow to the coronary arteries, brain, liver and kidneys.
The cuffs then deflate while the heart is contracting, which allows blood to flow
easily into the legs [15]. In fact, with the EECP returning more blood to the heart from
the lower extremities, the left ventricle is pumping against less pressure in the legs.
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Therefore it takes less effort and less oxygen demand for the left ventricle to pump more
blood to the system, hence reduced workload or reduced ventricular after load. The
increased blood flow to the coronary arteries enlarges the smaller blood vessels of the
heart and this enlargement gradually increases their blood carrying capacity [13].

The EECP treatment has a marked effect on cardiovascular hemodynamics.
Sequenced (from the calves upward) compression of the lower extremities during diastole
drives arterial blood backward, augmenting aortic diastolic pressure and causing
retrograde flow in the descending aorta. Augmenting aortic diastolic pressure increases
coronary perfusion pressure and, consequently, coronary blood flow. Coronary perfusion
pressure is the difference between aortic diastolic pressure and left ventricular
intracavitary pressure. The increase in coronary pressure and flow causes an increase in
shear stress in the coronary arteries.

14
3.4 Collateral Circulation
The EECP treatment is a non surgical, mechanical procedure that can reduce the
symptoms of angina or CHF, presumably by stimulating the opening, or formation of,
small branches of blood vessels (collaterals) to create a natural bypass around narrowed
or blocked arteries. Evidence to date suggests that the EECP treatment promotes the
growth of new blood vessels in the heart and improves blood flow to the areas that are
not getting enough blood and oxygen [11]. The improved blood flow decreases chest pain
symptoms.
Significant obstruction in one or more coronary arteries can create a pressure
difference between areas of the heart muscle that receive and those that do not receive
enough blood. Repeated and pulsed increases in pressure during diastole may stimulate
opening collateral channels across this pressure gradient within the heart muscle,
resulting in increased blood supply to deprived tissues.

3.5 Benefits
Clinical trials confirm the benefits of EECP treatment. There is an improved blood flow
to the heart thereby replenishing the deprived heart muscles. Counterpulsation increases
the stroke volume per unit work and; therefore, the efficiency of the left ventricle. There
is an elimination or reduction in the medications intake. Common medications for CHF
may include an ACE Inhibitor like Fosinopril, Enalapril, Lisinopril and many others;
Beta Blockers like Metoprolol, Carvedilol and some others; Diuretics (water pills) like
Furosemide, Bumetanide, Torsemide etc [17]. The patient shows an improved ability to
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exercise. The patient and their families report a noticeably greater ability to engage in
daily activity. It is a viable treatment option if:
I. 0ne has angina or congestive heart failure.
2. Medication does not provide adequate relief.
3. 0ne is not a candidate for surgery or angioplasty.
4. 0ne has already undergone surgery or angioplasty and angina has returned.
5. 0ne wants to explore all available treatment options.

3.6 Equipment
The EECP treatment uses a unique equipment to inflate and deflate a series of pneumatic
compressive cuffs around the lower extremities. The treatment is administered on a
padded table where three sets of electronically controlled inflation and deflation valves
are located. These valves are connected to specially designed adjustable cuffs that are
wrapped firmly but comfortably around the patient's calves, lower thighs and upper
thighs, as shown in Figure 3.2.
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The design of the cuff permits significant pressure to be applied to the arteries and
veins at relatively low air pressures. A microprocessor monitors the treatment process.
The timing for inflation and deflation is regulated by running the electrocardiogram
signals through the microprocessor [11].

3.7 Procedure
The patient receives EECP treatment for 35 hours divided into one sixty-minute session
five days per week. In EECP, long inflatable cuffs, similar to large blood pressure cuffs
are wrapped around both of the patient's legs; one at calf level, another slightly above the
knee and the third on the thigh. The cuffs are larger versions of the familiar blood
pressure cuff. While the patient lies on the bed, the leg cuffs are inflated with each
heartbeat. A pressure source inflates and deflates these cuffs, moving blood from the
lower limbs to the heart. The pressure is applied in sequence from the calves upward and
is synchronized with the heartbeat so that the increased blood flow is delivered to the
heart at the precise moment it is relaxing and blood flow through the coronary vessels is
at its peak. When the heart pumps again, the cuffs are deflated; this lowers resistance in
the vascular bed of the legs so that blood may be pumped more easily from the heart. The
patient's heart rate and rhythm are constantly measured during the process. The
microprocessor reads the patient's ECG and deflates the cuffs at the onset of each
heartbeat and inflates as each heartbeat ends. When the cuffs inflate, they do so in a
sequential fashion, so that the blood in the leg is pushed upwards towards the heart.
During diastole, the cuffs inflate sequentially from the calves proximally. This action
results in an increase in diastolic pressure, generation of retrograde arterial blood flow
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and an increase in venous return. The cuffs are deflated simultaneously just prior to
systole, which produces a rapid drop in vascular impedance, a decrease in ventricular
workload and an increase in cardiac output. The venous return and cardiac output is
increased by the compression of the vascular bed of the legs. The decompression of the
cuffs during systole permits systolic unloading and decreased cardiac workload because
of rapid and simultaneous decompression.

3.8 Summary
In the short term, this method of therapy is thought to deliver more oxygen to the
ischemic myocardium by increasing coronary blood flow during diastole, while at the
same time reducing the demand for oxygen by diminishing the work requirements of the
heart. Long-term benefit is expected to result as coronary collateral flow to ischemic
regions of the myocardium is increased.
Clinical trials have demonstrated that the beneficial effects of EECP, including
increased time until onset of ischemia and a reduction in the number and severity of
anginal episodes. These effects are not only sustained between treatments, but may
persist for several months to two years after completion of a course of therapy.
The EECP treatment increases blood flow 22-26% to the carotid arteries to the
brain, 20-42% to the coronary arteries, and 19% to the renal artery. It increases the heart's
output (stroke volume) by 12% and increases blood flow to areas not getting enough
oxygen in the heart [151 The ECP is FDA approved for Coronary Artery Disease and has
been shown effective in the treatment of ischemic conditions, including glaucoma,
angina, coronary artery disease, stroke and brain injury.

CHAPTER 4
HEART RATE VARIABILITY

This thesis is a study to measure the changes in heart rate variability due to the activity of
the autonomic nervous system caused by the EECP treatment. It has been proved that
rhythms can be markers of normal functional states [18]. Heart rate is one of the most
familiar measures of cardiovascular status. The term heart rate is commonly associated
with average heart rate but it is a well-known fact that the heart rate varies on a beat-tobeat basis due to cardiovascular control systems such as the ANS. The mean heart rate is
largely determined by a balance between the mean levels of activity in the cardiac
sympathetic and parasympathetic nerves. A decrease in vagal activity can be
compensated for by a decrease in sympathetic activity as far as the average rate is
concerned.

4.1 History of HRV
Various cardiovascular variables, such as heart rate and blood pressure, fluctuate from
one beat to another. HRV is measured on a beat-to-beat basis. Although the temporal
fluctuations in cardiovascular signals were noted in ancient times, physicians overlooked
for a long time the possible significance of beat-to-beat fluctuation of cardiovascular
signals [19]. This variability was treated as noise to be either ignored or averaged out.
With the advent of high-resolution electrocardiography instruments and digital
computers with high calculation capacity, it has been possible to measure the subtle beatto-beat fluctuations in cardiovascular signals. Also, the computation of heart rate
variability using various software languages like LabVIEW and MATLAB, and tools like
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power time frequency methods, frequency domain methods and time domain methods to
assess the frequency and amplitude of the oscillatory components of heart rate behavior
has been possible. Recent studies have shown that decreased fluctuation of RR intervals
is not noise, but implicates an increased risk for arrhythmic events and an increased
mortality rate in patients with a previous myocardial infarction [20]. Time domain and
frequency domain measures of heart rate variability have provided prognostic
information and also made it possible to perform noninvasive studies on the significance
of changes in the regulation of heart rate behavior. In this research the author has used the
method of power spectral analysis (frequency domain analysis) and SDNN (time domain
analysis) to analyze if the EECP treatment affected HRV in a significant way.

4.2 Background
The heart is designed to match cardiac output with the needs of the body. Sudden changes
in heart rate are common and expected in response to physical or mental stress and
exercise. Even in the absence of external perturbations, the normal heartbeat is not
characterized by clockwise regularity [18]. This fluctuation around the mean heart rate is
called heart rate variability (HRV). HRV therefore is a reflection of the cardiovascular
control exerted by the sympathetic and parasympathetic divisions of the autonomic
nervous system (ANS) on the heart that helps regulate cardiac output [21]. For a healthy
heart, the heart rate increases as one inhales and decreases at exhalation. HRV is also
associated with the balance of the fight or flight response and the relaxation response
branches of the ANS.
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4.3 Physiology
The HRV is affected by every system that modulates the autonomic nervous system. The
heart rate at any time represents the net effect of the vagus nerves, which slow it and the
sympathetic nerves, which accelerate it. In resting conditions, both autonomic divisions
are thought to be tonically active with the vagal effects dominant [19]. For the vasomotor
system the blood pressure is sensed by the baroreceptors and the sympathetic and the
parasympathetic branches integrate this information [20]. The resultant effect is a
variation in both heart rate and blood pressure. Therefore, blood pressure and heart rate
interact forming a closed loop. This creates an oscillation called the Mayer waves or the
10 seconds rhythm. For the thermoregulatory system, it is reported that the system causes
slow drifts in the HRV signal [21]. For the Renin-angiotensin system, the increase or
decrease of body fluids and the intake of salt can modify the HRV signal. The bridge
between the Renin-angiotensin system and the cardiac system is the sympathetic branch
[22]. The effect is a slow variation in the RR time series. For the central nervous system,
emotional states can modify the HRV. Intrinsic periodic rhythms that influence the heart
rate variability are [23]:
1. Respiratory sinus arrhythmia
2. Baroreceptor reflex regulation
3. Thermoregulation
4. Neuroendocrine secretion
5. Circadian rhythms
6. 0ther, unknown rhythms
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4.4 Applications of HRV
The greater the variability in heart rate, the better is the state of the ANS and cardiac
system. HRV is a noninvasive test of cardiovascular autonomic regulation. Specifically,
HRV is a measurement of the interaction between sympathetic ("fight or flight" energy
mobilization) and parasympathetic (the opposite of the sympathetic activity or
"relaxation" response) activity in the nervous system that controls the heart, intestines,
and other organs. In general, higher HRV is desirable; lower HRV has been found to be
a significant predictor of cardiac mortality and morbidity and other diseases.
The HRV is a promising yet complicated measurement that still has many
unresolved issues. In this research the author looked into the high frequency region of
the power spectrum as the high frequency (HF, 0.15-0.4 Hz) component is relatively well
established as a measure of parasympathetic activity. To remove the possibility of
conflicting results arising from different measurements of HRV and data collection
methods, the author performed the HRV measurements in standardized conditions in
order for the data to be reliable and valid. When collecting data from subjects, data was
collected around the same time each day. 0ther factors like age, sex, position, breathing,
smoking and medications which influence HRV were standardized. Breathing was
standardized by each subject following paced breathing protocol at 12 breaths per minute.
The quantization of the variability in cardiovascular signals provides information about
the autonomic neural regulation of the heart and the circulatory system. Several factors
have an indirect effect on these signals as well as artifacts and several types of noise are
contained in the recorded signal. The dynamics of RR and QT interval time series have
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also been analyzed in order to predict a risk of adverse cardiac events and to diagnose
them.
Patients with heart disease underwent the EECP treatment for one hour and the
ECG reading was collected pre and post treatment for 5 minutes for the purpose of
assessing time domain indexes (SDNN) and frequency domain indexes (LF and HF) of
HRV. The subjects followed paced breathing, the details of which will be explained in
chapter 5. Time and frequency domain indexes of HRV are high in healthy subjects and
decline proportionally with the severity of heart failure. Several studies have shown
lowered heart rate variability in patients with chronic heart failure (CHF) [24]. The author
sought to assess the prognostic value of heart rate variability due to the EECP treatment
on patients with heart problems. HRV was assessed from calculation of the mean R-R
interval and its standard deviation measured on short-term i.e. 5 minute
electrocardiograms. The smaller the standard deviation in R-R intervals, the lower is the
HRV.

4.5 Frequency Domain (Power Spectrum) Analysis
Power spectrum analysis decomposes the heart rate variability signal into its frequency
components and quantifies them in terms of their relative intensity, or power. This
analysis provides the basic information of how power (variance) distributes as a function
of frequency. Independent of the method used, only an estimate of the true power
spectral density of the signal can be obtained by proper mathematical algorithms; i.e.
each mathematical algorithm does not yield an actual value of the power spectral density
of a signal, but only an estimate.
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The heart rate power spectrum can be analyzed in two major ways: (1) Fast
Fourier transformation and (2) autoregressive model estimation, which are generally
classified as nonparametric and parametric methods, respectively. As was utilized in this
study, Fast Fourier transformation (FFT) describes a signal as a sum of various sinusoids
at fixed and equally spaced frequencies; i.e., the output of several sinusoidal oscillators,
the amplitudes and phases of which are described by FFT. The advantages of such
nonparametric methods include the simplicity of the algorithm used (i.e. FFT), and the
high processing speed. The advantages of the parametric methods are smoother spectral
components that can be distinguished independent of preselected frequency bands, easy
post processing of the spectrum with an automatic calculation of low and high frequency
power components with an easy identification of the central frequency of each
component, and an accurate estimation of the power spectral density, even on a small
number of samples on which the signal is supposed to maintain stationary.
The Fourier transform is a signal processing technique that is used to represent a
function in the time domain as a function within the frequency domain. It does this by
representing the components of a non-periodic signal as a sum of complex exponentials
or sinusoids. The following is the equation for the Fourier transform [24]:

where X(co) represents the Fourier transform of time function x(t), and e j represents the
-

complex exponentials or sinusoids that make up the signal. Essentially the Fast Fourier
transform is a computer algorithm used to efficiently compute the discrete time
equivalent of the continuous time Fourier transforms. 0nce the frequency domain
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analysis is completed using the Fast Fourier transform, the frequency content of the
power spectrum can be analyzed.
Three major frequency bands can be distinguished in a power spectrum, where
each is generally associated with different systems that control heart rate and calculated
from short-term recording of approximately 5 minutes (Figure 4.1). The computed
spectrum represents the distribution of the power density across the frequency range of
interest by decomposing the heart rate variability signal into its frequency components.
Power spectral analysis of short segments of five minutes of beat to beat heart rate
variability (PSIHRV) reveals three distinct peaks: A very low frequency range (VLF,
0.02 - 0.05Hz), a low frequency range (LF, 0.05 - 0.15Hz) and a high frequency range
(HF, 0.15 - 0.4Hz) as shown in the Figure 4.1. The energy in the HF is vagal mediated,
the energy in the LF and VLF are due to both sympathetic and parasympathetic systems.
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The high frequency (HF) band, ranging between 0.15 Hz and 0.4 Hz, is associated
with parasympathetic activity and is influenced by respiratory sinus arrhythmia. A
predominant peak usually occurs at the respiration frequency; therefore, depending on
respiratory rate, the respiratory peak may not be within this HF range. For example, the
respiration peak may reside around or above 0.15 Hz for respiratory rates below 9 breaths
per minute or above 0.4 Hz for rates above 24 breaths per minute. Consequently, the
maximum HF range is not limited to 0.4 Hz because for respiration rates above 24
breaths per minute, the respiratory peak begins to move into a higher frequency region.
The low frequency (LF) band ranges between 0.05 Hz and 0.15 Hz. The LF
component is, to some extent, generated by baroreceptor modulation of sympathetic and
vagal nervous tone [25]. It has been widely accepted that the low frequency band can
serve as an indicator of both parasympathetic and sympathetic nervous system activity
[26].
The third major frequency band that can be distinguished is the band of
frequencies lying between 0.02 Hz and 0.05 Hz known as the very low frequency (VLF)
band. The physiological origin of these very slow fluctuations is still to be determined;
however, it has been suggested that variations in the activity of the renin-angiotensin
system and thermoregulation are of importance.
Since the LF band is modulated by both parasympathetic and sympathetic
activity, there is no frequency band in the power spectrum analysis of heart rate
variability that yields a direct assessment of the sympathetic nervous system. As a result,
an indirect measure has been established. The ratio of LF to HF power (LF/HF power
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ratio) may be considered to be a measure of sympathovagal balance, a conclusion
supported by many experimental and clinical studies [27].
The measurement of VLF, LF, and HF power components is usually made in
absolute values of power (milliseconds squared). In this study, the LF and HF have been
normalized in two ways. 0ne, the LF and HF values were normalized to five minutes as
5LF and 5HF respectively, to standardize the data, as the length of each subject file was
different. LF and HF may also be measured in normalized units, which represent the
relative value of each power component in proportion to the total power minus the VLF
component. The representation of LF and HF in normalized units emphasizes the
controlled and balanced behavior of the two branches of the autonomic nervous system.
Moreover, the normalization tends to minimize the effect of the changes in total power on
the values of LF and HF components. Hence, LF and HF have been normalized to
normalized low frequency (NLF) and normalized high frequency (NHF), respectively.
Nevertheless, normalized units are always quoted with absolute values of the LF and HF
power in order to describe completely the distribution of power in spectral components.

4.6 Time Domain (SDNN) Analysis
The most reliable score in HRV, and the measure of variability itself, is the SDNN
(standard deviation of normal to normal intervals). This index is the one used to predict
mortality [28]. The quantification of HRV in time-domain analysis is based on several
statistical measures or indexes (such as the mean or the standard deviation) of the RR
time series. Time-domain indexes fall in two categories: indexes for short and long time
measurements. 0ne of the most important and popular time-domain HRV parameters is
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SDNN, which reflects the overall variability over a specified time interval [25]. However,
the SDNN value depends on the length of the recording.
Due to the standardized steady measurement condition of any 5-minute HR
recording, its SDNN value is typically significantly lower than the SDNN measured
during a 24-hr period, which includes the night sleep hours and periods of physical and
mental activity with significantly higher HR readings. In this study the SDNN was
calculated for five-minute recordings. The time domain measures of HR variability are
calculated by statistical analyses (means and variance) from the lengths of successive RR intervals. SDNN is considered to reflect both the sympathetic and the parasympathetic
influence on HRV. SDNN mostly reflects the very-low-frequency fluctuation in heart rate
behavior. It cannot detect subtle changes in heart rate dynamics, because the fast changes
in heart rate occurring within a few seconds or minutes are lost under the majority of
slower changes. All time and frequency domain measures of HR variability could be
affected by artifacts, and these measures require data from which these artifacts have
been eliminated.

CHAPTER 5
EXPERIMENTAL PROCEDURES AND METHODS

The data used in this experiment was obtained at the University Hospital, Department of
Cardiology, The University of Medicine and Dentistry of New Jersey (UMDNJ) in
Newark, New Jersey. This chapter provides the details of the experiment, including
subject background, equipment configuration, and data analysis methods. In order to
analyze and compare the data, there were three groups of subjects- Patients, Normals and
Controls. The study for the controls was conducted at New Jersey Institute of Technology
(NJIT) while the data for the normals and patients was acquired at UMDNJ.

5.1 Subject- Patient
5.1.1 Patient Background and Preparation
In this research, studies were conducted on people who had myocardial ischemia or heart
failure. The patients had been recommended for EECP treatment. The preparation for the
treatment involves almost no preparation on the subject's part except for wearing light
fitting pants to avoid chafing and skin irritation from the natural movement of the
pressurized cuffs. There were seven patients who had the EECP treatment recommended
to them. 0f the seven patients, six were myocardial ischemic patients and one was a heart
failure patient. The patients had to be non-smokers. The patients were labeled as A, B, C,
D, E, F and G. The data was collected from patients who had no caffeine intake for at
least three hours and no food intake at least two hours before the data acquisition.
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5.1.2 Data Acquisition
Subjects received 35 one-hour EECP treatments over a seven-week period. Data of
patients having heart conditions were collected for the pre and post one-hour treatment
period. The electrocardiogram, respiration and blood pressure signals were collected for 5
minutes pre and post treatment. The patients followed paced breathing at 12 breaths per
minute. Details of the paced breathing equipment and procedure are given in section 5.5.

5.2 Subject- Normal
5.2.1 Normals Background and Preparation
To compare the data obtained from the patients who underwent the EECP treatment,
there were another group of subjects, who were healthy but underwent the EECP
procedure. This set of people was defined as Formals. They underwent a total of three
EECP sessions during three consecutive days. Formals had no history of myocardial
ischemia known to the physician. They were healthy individuals. There were three
Formals. In this research the normals were labeled as H, I and J. They also followed
paced breathing at the rate of 12 breaths per minute. The normals were instructed on:
1. No caffeine intake for at least three hours before the data collection.
2. No food intake at least two hours before the data acquisition.
3. They should be non-smokers.
4. Healthy individuals.
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5.2.2 Data Acquisition
Formals received 3 one-hour EECP treatments over a period of three days. The data were
collected for the pre and post one-hour treatment period. As with the patients, the
electrocardiogram, respiration and blood pressure signals were collected for 5 minutes
pre and post treatment. The normals followed paced breathing at the rate of 12 breaths
per minute, the details of which are given in Section 5.5.

5.3 Subject- Control
5.3.1 Controls Background and Preparation
0ther than the patients and normals that underwent the EECP treatment, there was
another group of subjects, who had no presence of heart disease and did not undergo the
EECP procedure. The ECG, respiration and blood pressure signals were collected from
these subjects. These set of people were defined as Controls. There were five controls.
The prerequisites for the controls were:
1. Fo caffeine intake for at least three hours before the data collection.
2. Fo food intake at least two hours before the data acquisition.
3. They should be non-smokers.
4. Healthy individuals.
5. In the same age group of 23-27 years.
The average age group for the controls was 25 years. The data was collected in
the biosignals research laboratory at FJIT. The data from the 5 controls were collected on
the same day, one control following the other.
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5.3.2 Data Acquisition
The electrocardiogram, respiration and blood pressure signals were collected for 5
minutes before and after an hour. In the intermediate hour, they rested or indulged in nonstressful activity as any kind of activity increases the sympathetic activity. An increase in
the sympathetic activity increases the low frequency activity of the HRV spectrum.

5.4 Testing Procedure
A RESP 1 impedance pneumograph (UFI, Morrow Bay CA) was used to convert both
respiration and ECG data into analog signals. The Resp 1 is a self balancing, stand-alone
signal conditioner which converts changes in thoracic impedance resulting from
respiration, into a high-level respiration signal. A front panel meter shows respiration
activity for easy checkout. A 9V battery powered the Resp 1 impedance pneumograph.
The ECG recordings were obtained using surface silver-silver chloride disposable
electrodes. (Myotronics Research, Seattle, WA). The skin underlying the electrodes was
dried with alcohol and the electrodes were placed on the surface of the upper left chest
and upper right chest and were affixed to the skin. The exact placing of the electrodes on
the chest depends on the strength of the ECG waveform, which is monitored through the
Resp 1 's output to the computer. The ECG and respiration recordings were taken through
the Respi impedance pneumograph. The ground electrode was placed on the left arm
and approximately 20 centimeters away from the elbow towards the hand. Real time
blood pressure data were collected as analog signals through the Colin 7000 (San
Antonio, TX) noninvasive arterial tonometry device. This device consisted of a sensor
positioned over the left radial artery at the wrist and an occlusion cuff positioned around

32
the upper left arm. The Colin 7000 was calibrated before each data acquisition. Data were
collected using LabVIEW v.5.0 software, a data coliection program including a BFC 800
interface board and a 12-bit analog to digital (A/D) DAQ Card-700 board (Fational
Instruments, Inc., Austin TX). The data were imported as three channels. The LabVIEW
software was also used to analyze the data using power spectral analysis. The converted
digital data were imported to a Dell Fotebook via the Fational Instruments data
acquisition card, FI PCI-6025E.

5.5 Paced Breathing
While recording the data, the patients, normals and controls followed paced breathing.
With each subject foliowing paced breathing, i.e., controlled breathing at 12
breathsIminute, the data were standardized, so that the respiratory peak occurred in the
HF region at 0.2 Hz. Paced breathing was done using a paced breathing box, which has a
series of LED lights, flashing in sequence at the rate of 12 breaths per minute. Figure 5.1
shows the plot of a patient who followed paced breathing.
Figure 5.1 is the plot showing the heart rate variability of patient MS. Referring to
the left hand side of the plot, SF gives the value of the sampling frequency at the rate of
250 sample points per second. HF area shows the value of high frequency power in the
region of 0.15-0.4 Hz in the heart rate power spectrum. The LF area shows the value in
the low frequency region. Referring to the second graph of the respiration power
spectrum in figure 5.1, the peak at 0.2 Hz validates the fact that the patient was breathing
at 12 breathsImin. The third graph shows respiration as a function of time. It can be easily
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identified by its periodical waveform. Time for each data file in minutes was also
calculated.
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5.6 Data Analysis
5.6.1 Programs
The ECG, BP and RESP data were the inputs to three programs used to calculate the
HRV power spectrum. A sample data file is given in the Appendix A. LabVIEW 5.0 was
used to analyze the data.

Figure 5.2 Plot shows the channels of respiration, biood pressure and ECG, respectively.
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Program A was used to identify the channels of ECG, respiration and blood
pressure. Figure 5.2 shows the plats generated by program A. Program A is given in
Appendix B. In Figure 5.2, channel 0 was respiration, channel 2 was blood pressure and
channel 1 was ECG.
The output from program C generated heart rate and respiration power spectra
versus frequency. Program C is given in Appendix F. The basic requirement for the
computation of the HRV spectrum is a noise free record of the signal lasting five minutes.
Foise in the data usually occurs from improper placing of the electrodes, coughing or
movement by the subject or not following the pacing signal. Each data file is
approximately five minutes in length. Since the data was real time data, in some cases,
there was presence of noise in the 5-minute file.
The criterion for an acceptable segment was a relatively sinusoidal or periodic
respiration waveform. Hence, an acceptable segment of minimum 15000 sample points
i.e. 1 minute was used as a criterion to extract signals from the original file. For this
purpose, a data extraction program (Program B) was used. The program is given in
Appendix B. Figure 5.3 and Figure 5.4 show the original and the extracted file of patient
B, respectively. Channel 0 shows the respiration waveform of patient B in both the
figures. In the original file, the sample points are 108000. Due to the presence of noise in
the data, the power spectral analysis program detected the noise as peaks and gave
incorrect values for LF and HF power. Regions in channel 0 where there was
discontinuity (sample points 0 to 13000) and irregular peaks (sample points 39000 and
103000) could not be used for data extraction. A sudden high peak at point 39500 and an
irregularity at 71000, made it impossible to use the segment of 25000 to 100000. Since
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the criterion was at least a segment of 15000 sample points, hence points 40000 to 70000
were extracted from the original data file to perform the spectral analysis. Figure 5.4
shows the extracted data file with 30000 sample points.

Figure 5.3 Plot for patient B with original data points of 108000.
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Figure 5.4 Plot for patient B with extracted data points of 30000.
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Figure 5.5 Plot tor patient 13 showing a data tile tor patient 13 where no data could be
extracted.
Figure 5.5 shows a data file of patient B, where no acceptable region of minimum
15000 sample points could be found. The presence of innumerable irregular respiration
peaks observed from channel 0 in Figure 5.5 and absence of periodic respiration
waveform made it impossible for the author to extract a reasonable segment to perform
the data analysis. Files with these problems could not be used for spectral analysis, but
were still counted as session numbers when performing the statistical analysis.
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The recorded ECG, BP and respiration files were approximately five minutes in
length, taken before and after each treatment. The recorded ECG signal was sampled at
250-samplesIsec to precisely locate the QRS complex. The blood pressure was also
sampled at 250-samplesIsec. Subjects followed paced breathing at approximately 12
breaths per minute.

5.7 Power Spectral Analysis
Spectral analysis (frequency-domain analysis) quantifies the frequency content. It detects
periodic oscillations (amplitude and frequency) and it has been employed in a great
variety of time series processing [28]. It is well known that HRV has oscillations at
different frequencies that are originated by different physiological systems [29]. These
oscillations are transmitted to the heart by the sympathetic and parasympathetic systems.
It is also well established that high frequency oscillations (0.15-0.4 Hz) are vagally
mediated. Low frequency oscillations (0.05-0.015 Hz) are due to both parasympathetic
and sympathetic systems. The starting point in every frequency-domain analysis is to
perform the power spectral estimation of the signal [30]. The next step is to quantify the
result of spectral estimation. 0ne way to do this quantification is to divide the power
spectrum in bands and to quantify the energy (by integration) in each one.
The location of the R peaks was detected using a peak detection algorithm
incorporated in program C to compute the LF and HF power. Figure 5.6 shows the
execution window of the peak detection algorithm. The troughs in the program show the
missed peaks and the crests show the non-real peaks detected.
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The respiratory signal was analyzed to determine the respiration peak. In. Figure
5.7, the second graph shows that the respiration peak is close to 0.2 Hz. The HF peak has
been associated with respiration frequency and is mediated by parasympathetic pathways.
The results were displayed as a power spectrum, in which the area under the curve
represents the degree of variability. The peak of the curve occurs at or near the respiration
frequency.

Figure 5.6 Window showing the peak detection. The troughs in the first plot are the
missed peaks in the second plot.

From Figure 5.7, the LF and HF were computed as LF area and HF area. The
length of the file was generated as the time of record in minutes. Using these basic
values, calculations were conducted for normalized high frequency (FHF) and
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normalized low frequency (NLF). Since every file was of a different length, depending
on the length extracted from the original data file, the LF and HF generated from the
program were normalized to five minutes as 5LF and 5HF, respectively. An example of
the calculations involved for one subject is shown in Table 5.1.

Figure 5.7 Window showing the power spectral analysis.

Low Frequency normalized to 5 minutes (5LF) was defined by (5.1)

High Frequency normalized to 5 minutes (5HF) was defined by (5.2)

Formalized High Frequency (FHF) is defined by (5.3)

and, Formalized Low Frequency (FLF) is defined by (5.4)

Table 5.1 Table of Calculations Involved for Patient F Generated from Using Equation
5.1 Through Equation 5.4

The calculated values of FLF and FHF were used as a basis for statistical
analysis. Sometimes, the patients missed some of the sessions. In that case, the particular
session was not used in the calculations of the session numbers. The author was unable to
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analyze some of the data files due to the unavailability of a good segment of respiration
waveform. Therefore, the data file for the day was valid only if analyzed data files were
available for pre and post session. The values of NLF pre and post treatment were
compared against the sessions. Figure 5.8 is a graph plotted to observe any trends for
FLF versus session numbers. The criteria were same for FHF, FLFINHF. Also, graphs
were plotted for FHF and FLFINHF against session numbers as shown in Figure 5.9 and
Figure 5.10. Table 5.2 is the table of FLF values for patient F used for plotting Figure
5.8. Similarly Figure 5.9 and Figure 5.10 are graphs for FHF and FLFINHF against
session numbers, respectively.
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Figure 5.9 Graph showing the plot of FHF versus session numbers for patient F.
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5.8 Standard Deviation of Normal to Normal Intervals
After performing the R wave peak detection in the spectral analysis of the data file in
LabVIEW 5.0, the filtered file obtained was stored as an interbeat interval (IBI) file. This
file was then executed through a MATLAB program to generate the standard deviation of
normal-to-normal (SDFN) intervals. The algorithm for calculating the SDNN values is
given below:
1. Calculate the average of the original data values (observations).
2. Subtract the average from each original data value. This is the deviation or
deviation from mean.
3. Square the resulting number. This gives the set of squared deviation values. It also
eliminates any negative values from the equation.
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4. Sum the squared values (simply add them all together), which gives the sum of
squared deviations.
5. Count the total number of observations (F) MINUS 1. It is called F-1.
6. Divide the sum of squared deviations by (N-1).
7. Take the square root of the whole thing. This value provides the standard
deviation.
The program also calculated the number of sampling points. The code for the MATLAB
program is given in Appendix B as program D. Table 5.3 shows the SDFF values for the
patient F pre and post treatment. These values were plotted against the session numbers,
the graph of which is shown in Figure 5.11.

Figure 5.11 Plot for SDFF and session number for patient F.

5.9 t-test Analysis
The t-test is a parametric test of data analysis. The t test assumes that the research
involves the estimation of at least one variable [31]. It involves certain assumptions about
the variables, which is, that the variable is normally distributed in the overall population.
It tests whether two group means are different or not. Both groups must be independent
i.e. nothing in one group is related to the other group. It is also used to show difference
among groups. If the groups are related, and the differences are compared, a variation of
the t test, called a paired t or a correlated t test can be used. Table 5.4 and Table 5.5 show
the t-test values conducted on the patient F's FLF pre and post values. For the
Hypothesized Mean Difference, the test asks what is the probability of obtaining the
given results by chance if there is no difference between the means. In the Table 5.4, the t
stat value shows the t value calculated from the data. The p (T<t) two-tail value shows
the probability of getting the calculated t value by chance alone. That probability is
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extremely low, so the means are significantly different. The t Critical two-tail shows the t
value that wouid needed to exceed in order for the difference between the means to be
significant.

When comparing two groups, the t-value will be positive if the first mean is larger
than the second and negative if it is smaller. 0nce the t-value is computed, to test the
significance, a risk level is set, called the alpha level. The alpha level also called the
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significance level is the odds that the observed result is due to chance. In this test, the
alpha level was set to 0.05. This means that five times out of a hundred we would find a
statistically significant difference between the means even if there were none. A one- or
two-tailed t-test is determined by whether the total area of alpha is placed in one tail or
divided equally between the two tails.

In a one-tailed t-test, all the area associated with alpha is placed in either one tail
or the other. Selection of the tail depends upon which direction the t value would be (+ or
-) if the results of the experiment came out as expected. The selection of the tail is made
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before the experiment is conducted and analyzed. The one-tailed t-test is performed if the
resuits are interesting only if they turn out in a particular direction. A one-tailed t-test in
the positive direction is illustrated in Figure 5.11. The two-tailed t-test is performed if the
results would be interesting in either direction. A two-tailed t-test divides alpha in half,
placing half in the each tail. Figure 5.12 shows the two-tail t-test.

CHAPTER 6
RESULTS AND DISCUSSION OF ANALYSIS

The analysis of the data was focused in three main categories. First, a comparison of the
FLF values for pre and post session for every subject was performed, employing graphs
of FLF against the sessions, and t tests. Fext, a comparison of FHF values against
session numbers was performed for pre and post session of all the subjects. Also, a
comparison of FLF/NHF values with the session numbers was made to study the
sympathovagal balance as the ratio of LowIHigh (LFIHF) frequency. Lastly a comparison
of the SDFF values was made against the session numbers. This chapter will detail the
results of the analyses performed in this research and provide a discussion of these
findings in comparison to normals and controls.
As discussed in Chapter 5, a power spectral analysis was performed on the ECG
data recordings. For this study, the blood pressure data was not used. The blood pressure
data can be used to study the blood pressure variability as a part of future research. The
tables for the calculations and graphs of all the patients, normals and controls are given in
Appendix C, D and E, respectively.

6.1 Results of the NLF Comparison
Table 6.1 shows the t-test analysis conducted on the FLF vaiues of all the patients. Table
6.2 is the table of t-test values for the normals while Table 6.3 is the t-test values for the
controls. These t-test values are paired since the two sets of data — FLF pre and FLF
post, are independent of each other.
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Table 6.1 Table Showing the T Test Values for FLF of All the Patients
t Test: Paired Two Sample for Means
-

Table 6.2 Table Shows the T Test Paired Two Sample for Means for the Formals
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Table 6.3 Table Shows the T Test Paired Two Sample for Means for the Controls

Comparing the FLF values of the normals and controls with the patients, no
significance was observed from the t-test analysis to prove that EECP treatment affected
the HRV for the normalized low frequency. A variety of studies have demonstrated that
acute interventions that increase sympathetic nervous system activity, such as orthostatic
perturbations, mental stress, or handgrip exercise increases the LF spectral power of heart
rate [31]. In addition to acute perturbations of cardiac sympathetic nerve activity,
feedback oscillations generated by the baroreceptor reflex also appear to contribute to LF
spectral power of heart rate.

6.2 Results of the NHF Comparison
In an effort to quantify the changes that are observable via visible analysis for purposes
of graphical observation, the FHF data were plotted for pre and post session against the
session numbers. Figures 6.1 and 6.2 are the FHF versus session number plots for
patients B and D, respectively. Sessions from day 9 through day 14 in Figure 6.1 are
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missing. The reason was that the author was unable to analyze some of the data files due
to the unavailability of a good segment of respiration waveform. Therefore, the data file
for the day was valid only if analyzed data files were available for pre and post session.
The total numbers of sessions were the sessions that the patients actually attended. That
was the reason why patient D had 24 sessions instead of the 35 sessions.

Figure 6.1 Graph showing the comparison of NHF values for pre and post session for
heart failure patient B.

Figure 6.2 Graph showing the FHF values for patient D.
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From the plot of FHF against session numbers for pre and post treatment values
for heart failure patient B (Figure 6.1), it is observed that the FHF values for post
treatment increase in the third to the fifth week period. This might be an indicator that the
maximum effect of the treatment happens in the third to fifth week period of the EECP
treatment. From then onwards, the post sessions normalized high frequency show no
marked increase. This trend was not observed for any of the other patients. Figure 6.2
shows the plot of patient D against the session numbers. Fo particular trend was observed
from the plot to substantiate the trend observed in the heart failure patient. Patients B and
D were the subjects who attended the maximum number of EECP treatment sessions for
the author to observe any trends. Patient B attended 33 sessions while patient D attended
24 sessions. Since the author was looking at 20 or more session numbers to observe any
trends, the database of the remaining patients A, C, E, F and G were not significant
enough to observe any trends. The plots showing the variation of FLF, FHF and
FLF/NHF against the session numbers for all the patients have been shown in Appendix
C.
Tables 6.4, 6.5 and 6.6 show the values of t-test for two-paired sample for means
for patients, normals and controls, respectively. In the absence of significance observed
from the t-test values, the author is unable to propose statistically that the EECP
treatment affects the heart rate variability in a comprehensive way.
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Table 6.5 Table Showing the T Test Values for FHF of All the Formals
NHF for Normals

t-Test: Paired Two Sample for Means
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Table 6.6 Table Showing the T Test Values for FHF of All the Controls

6.3 Results of the NLF/NHF Comparison
The LFIHF ratio increases in situations where sympathetic activity is known to be
increasing. Tables 6.7, 6.8 and 6.9 show the t-test values of FHF values pre and post
treatment for patients, normals and control, respectively. Again, the lack of significance
in the t-test values fails to assess any changes in the heart rate variability.
Table 6.7 Table Showing the T Test Values for FLFINHF of All the Patients
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6.4 Results of the SDNN Comparison
In order to observe the SDFF values graphically to compare it against each session, the
pre and post values were plotted against the session numbers. Figure 6.3 shows the graph.
From all the graphs of all the patients, controls and normals; no particular trend was
observed.

Figure 6.3 Graph showing the variation of SDFF values against the session numbers for
patient G.

6.5 Discussion and Conclusions
An ideal method for clinical work would be a single HR variability index that could be
calculated reliably on the basis of a simple, widely available analytical method. At the
moment, there is no consensus about the best available index of HR variability for
clinical use, despite the efforts of the Task Force of the Forth American Society of
Pacing and Electrophysiology and the European Society of Cardiology to unify and
standardize the methodology [32]. Foisy data, artifacts, trends and ectopic beats are the
major practical problems encountered in HR variability measurements. In this research, a
minimum segment of one minute was used, with the respiration waveform as the criterion
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to obtain an acceptable length of file. The criterion for an acceptable segment was a
relatively sinusoidal or periodic respiration waveform (refer section 5.6.1, page 35).
Simple statistics of heart rate variability, such as the standard deviation of R-R intervals
in the ECG, can reliably predict the prognosis of cardiovascular diseases [33].
Sympathetic outflow is increased in case of heart failure [34]. Congestive Heart
Failure (CHF) is usually treated with medication. If medication is ineffective or the risk
of heart attack is high, doctors may usually recommend Coronary artery bypass surgery.
In cases where the medication is not effective or the bypass surgery failed, the patients
are prescribed the EECP treatment by their physicians. The major advantages of EECP
include the non-invasive nature of this therapy, the overwhelming rate of success and
lack of any significant complications associated with it. An increase in high frequency
post treatment is an indicator of increase in vagal activity and HRV.
Due to the lack of significance observed from the t-tests, the author failed to
prove that the EECP treatment affected the HRV. 0ne of the possible factors that caused
the HRV test to fail was the fact that subjects were already in the normal range. If the five
minutes normaiized LF and HF values were greater that 250, then the subject was
assumed to be in the normal range. Table 6.10 shows the values of LF and HF for patient
C who was in the normal range. In that case, an increase in variability would not be
expected. Subjects A, B, C, G, I and J were aiready in the normal range before the study
began, hence any trend or significance was not observed.
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Table 6.10 Table Showing the 5 Minute Formalized LF and HF Values for Patient E

0ver the period of the treatment, an increased HR variation was noticed for heart
failure patient B. A marked increase in the FHF was observed between weeks three and
five of the treatment. The remaining two weeks in the treatment, weeks six and seven,
showed no marked increase in value. As evident from Fig 6.1,which displays an example
of one subject data, the post FHF starts increasing around the third week till the fifth
week suggesting that there may be a shift in pre post ratios of NHF starting in week 5.
This was observed in the non-ischemic heart failure patient only. Future research would
help to follow-up this initial finding.
Since the controls rested for an hour before the post readings were collected, there
should not have been much variation between the pre and post LF and HF. For controls 1,
3 and 4 (Figure 6.4), drastic HR variation was observed. When collecting data from
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subjects, data was collected around the same time of the day. Other factors like age, sex,
position, breathing, smoking and medications which influence HRV were standardized.
Breathing was standardized by each subject following a paced breathing protocol at 12
breaths per minute. Mental stress could be one of the possible causes for the HRV
variation. If the controls became very relaxed over the period of data collection, then the
HF value would increase, which could be another causes for the HRV variation. This can
be verified with a longer database.

Figure 6.4 Plot showing the FHF pre and post data collection for controls.

The reliability of the heart rate variability study depends on a number of factors.
One set of variables is the physiological condition of the subject, such as, the diseased
state of the subject, type of disease, age, gender, medication or the treatment that the
subject is undergoing. The other set of variables include the technical aspects of data
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collection, such as, the position of the subject at the time that the data was collected,
caffeine, food and nicotine intake, the length for which the data was collected etc. Hence,
the reliability of heart rate variability depends on a number of variables. 0nce these
variables have been eliminated, with the help of different analysis tools like non-linear
method of analysis, wavelets on a substantial database, the heart rate variability and its
reliabilty can be measured.

CHAPTER 7
SUGGESTIONS FOR FUTURE RESEARCH

7.1 Suggestions for Future Work
As is often the case, this clinical study raises more questions than it is capable of
answering. In this research, the number of patients who underwent the EECP treatment
was seven. With a more extensive database, EECP could probably prove conclusively
whether it affects HRV substantially or not. Also, the number of normals was only three,
so it could not be concretely used as a comparison basis between the patients and
normals. It is highly recommended to have an extensive database for analysis of the
effect on heart rate variability by the EECP treatment, for the data pool was not as large
as that required of a medical conclusion. Though the author did not come to any novel
conclusions about the underlying data or the spectral and time-domain analyses, the
author is confident that additional research in this area would prove useful and medically
important.
Studying the increase in FHF over the period of 5-6 weeks for the heart failure
patient ES, with more detailed study, it can possibly be verified conclusively that EECP
treatment increases FHF within six weeks.
Currently, the primary indication for EECP treatment is chronic stable angina.
With more in depth research, maybe decreased HRV in people with heart conditions
could be used a marker that the EECP treatment may be used as a potential treatment
modality for heart failure patients, in whom invasive revascularization procedures do not
offer a survival. The EECP treatment may be particularly useful in patients considered
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high risk for revascularization procedures or in whom revascularization is not technically
possible.
The literature suggests that the variation and fluctuation of the heart rate in
relation to the mean heart rate is a function of cardiorespiratory physiology [34]. It has
been known for several decades that enhanced vagal tone has a salutary effect on the
electrophysiologic properties of the ventricle to prevent the emergence of life-threatening
ventricular arrhythmias in certain situations, particularly in post infarction and diabetic
patients. Hence, heart rate variability may offer information about sympathetic and
parasympathetic autonomic function and could serve as a measure of risk stratification
for serious cardiac arrhythmias and possible sudden cardiac death. Fotably, continuous
changes in the sympathetic-parasympathetic balance can be reflected in variations of the
sinus rhythm that oscillate around the mean heart rate.
Future work should include a more thorough examination of the data with more
analysis tools like wavelets, time frequency methods and non-linear methods. Since the
heart rate variability research lab at FJIT has excellent software tools in MATLAB,
LabVIEW and Wavelets, an extensive data pool would allow for a detailed study and
reach a fruitful conclusion.
A difficulty in analyzing data of this nature is that the patient tends to move or
shift while the data is collected. Even a slight movement can affect the data recorded. To
this effect, it is recommended that a marker system be developed to indicate in the data
files when events, such as coughing, shifting, moving hand etc occur during the
experiment. This would allow the researcher to properly identify motion artifact in the
data. This may be implemented using a button push marker system, with specific codes
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inserted into the data for various activities. A camera system may also be implemented
effectively to coordinate movements with data recordings.

7.2 Unanswered Questions
Two major questions concerning heart rate variability remain to be clarified. First, many
methods to measure heart rate variability have been reported, and it is very difficuit to
conclude which one is most appropriate for establishing normal values and for particular
patient subgroups. There is a need to standardize the measurement of heart rate variabiiity
and to quantify normal values under various circumstances, including patient age and
gender. Second, the sensitivity, specificity and predictive accuracy of this test require
much more prospective investigation. Correlations of this test with other risk
stratification measurements will be necessary to evaluate its independent predictive
value. The preliminary data available from this research does not allow for definitive
conclusions.
Furthermore, the value of heart rate variabiiity or any other risk stratification test
in patients who undergo revascularization of infarctiog myocardium requires assessment.
It appears that mortality after myocardial infarction is decreasing with the new and
aggressive therapeutic methods being used, and heart rate variability will have to be
evaluated in this setting. Similar evaluations need to be performed in other
pathophysiologic states such as congestive heart failure.

APPENDIX A
SAMPLE DATA FILE

A sampie data file of patient ES is given in this appendix. The first column represents
channel 0 that is, respiration. The second column shows channel 1 which is ECG, while
the third column shows channel 2, which is blood pressure. In some cases, during R wave
detection the r peaks were inverted, which meant that the ECG values were negative in
value, which was an indication that the ECG leads were switched. To counter this, the
program to analyze the ECG signal was multiplied by a factor of —1.
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APPENDIX B
PROGRAMS FOR THE STUDY

Three LabVIEW programs were used in the study to analyze the data. LabVIEW has two
panels in a program- Front panel, where the waveforms are generated and a back panel
where the graphical programming is executed. A Matlab program was used to calculate
the standard deviation of normal-to-normal intervals.
Program A was used to identify the three channels of respiration, ECG and blood
pressure. This program was also helpful to execute the original data file and obtain an
extracted data file by using a relatively periodic respiration waveform as criteria to
extract the data. Inputs to the program were the sampling rate and the name of the file to
be executed. 0nce the segment of the file was identified, it was extracted with the help of
program B. The inputs to the program were the start and end points of the segment of the
data file. The program then wrote to another spreadsheet file, which was then used for
spectral analysis. Then, Program C was used to obtain the values of LF and HF power as
well time of record. It also plotted the respiration and heart rate spectrum.
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Front Panel:
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Program B — To extract the data for the spectral analysis.

Main Diagram:
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Front Panel:
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Program C — To calculate the LF and HF power.
Main Diagram:
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Front Panel:

162:4 cohereninikei *
sped

HR Spectrums

Graph of Heart Rate power spectrum
2000000,1 -r
HF Area
1001J7
ALF Area
020,01

1500000,0

1000000,0 500000.0
0.0- 1
00

01

Time of record in minutes

0.2

03
Hertz

FREQUENCY

Resp Spectrum

Graph of Respiration power spectrum

F./71
---

1000000.0 800000,0 600000,1 000000,1 -

200000,1 0,1 -,
00

0,1

0:3

0,0

0:5

0:0

Plot 0

Respiration]

0,00,0-0,1-0,0-6,1 -,

00

I

.0

106.0

150,0

206,0

250,1

306,1

350,0

000,0

050,0

76

APPENDIX C
PATIENT DATA ANALYZED IN THE RESEARCH

This Appendix contains the data table and plots for patients A, B, C, D, E, F and G. The
tables contain the values of NLF, FHF, FLF/NHF and SDFF for pre and post session of
each patient. The sessions that had the data for pre and post treatment for the particular
day has been included. The plots show a comparison of pre and post session values for
each patient for FLF, FHF, FLF/NHF and SDFF.
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APPENDIX D
CONTROL DATA ANALYZED IN THE RESEARCH

This Appendix contains the data table and plots for five controls. The tables contain the
values of FLF, FHF, FLF/NHF and SDFF for pre and post session of each control. The
plots show a comparison of pre and post session values for each control for FLF, FHF,
FLF/NHF and SDFF. There were five controls; who have been treated as five sessions.
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APPENDIX E
NORMAL DATA ANALYZED IN THE RESEARCH

This Appendix contains the data table and plots for normals H, I and J. The tables
contain the values of FLF, FHF, FLFINHF and SDFN for pre and post session of each
normal. The plots show a comparison of pre and post session values for each normal for
FLF, FHF, FLFINHF and SDFF.
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